The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide

Neuro-Oncology

Volumn 17, Issue 12, 2015, Pages 1589-1598

  Rapkins, Robert W ^a   Wang, Fan ^b,c   Nguyen, Huy Tram N ^d   Cloughesy, Timothy F ^d   Lai, Albert ^d   Ha, Wendy ^a   Nowak, Anna K ^e   Hitchins, Megan P ^b   McDonald, Kerrie L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b STANFORD CANCER INSTITUTE   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

MGMT methylation; SNP; Survival

Indexed keywords

CYTOSINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; THYMINE; ALKYLATING AGENT; BIOLOGICAL MARKER; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MGMT GENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METHYLATION; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS; BRAIN NEOPLASMS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENOTYPE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHYLATION; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84942375312     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov064     Document Type: Article

References (25)

1. Burnet NG, Jefferies SJ, Benson RJ, et al., Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer. 2005;92(2):241-245.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131(6):1342-1350.
4. Stummer W, Nestler U, Stockhammer F, et al. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol. 2011;103(2):361-370.
5. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003.
6. Xu M, Nekhayeva I, Cross CE, et al. Influence of promoter/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents. Carcinogenesis. 2014;35(3):564-571.
7. Shete S, Lau CC, Houlston RS, et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer Res. 2011;71(24):7568-7575.
8. Walsh KM, Codd V, Smirnov IV, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet. 2014;46(7):731-735.
9. Walsh KM, Rice T, Decker PA, et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro Oncol. 2013;15(8):1041-1047.
10. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41(8):905-908.
11. Hawkins NJ, Lee JH, Wong JJ, et al. MGMT methylation is associated primarily with the germline C.T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol. 2009; 22(12):1588-1599.
12. Ogino S, Hazra A, Tranah GJ, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007;28(9): 1985-1990.
13. Kristensen LS, Nielsen HM, Hager H, et al. Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP. Lung Cancer. 2011;71(2):130-136.
14. Kristensen LS, Treppendahl MB, Asmar F, et al. Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci Rep. 2013;32: 789.
15. Leng S, Bernauer AM, Hong C, et al. The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas. Clin Cancer Res. 2011;17(7):2014-2023.
16. McDonald KL, Rapkins RW, Olivier J, et al. The T genotype of the MGMT C.T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. Eur J Cancer. 2013;49(2):360-368.
17. Candiloro IL, Dobrovic A. Detection of MGMTpromoter methylation in normal individuals is strongly associated with the Tallele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila). 2009;2(10):862-867.
18. Oberstadt MC, Bien-Moller S, Weitmann K, et al. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. BMC Cancer. 2013;13:617.
19. Lalezari S, Chou AP, Tran A, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013;15(3): 370-381.
20. Christians A, Hartmann C, Benner A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PloS One. 2012;7(3):e33449.
21. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg. 2001;95(4):651-659.
22. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
23. Egan KM, Thompson RC, Nabors LB, et al. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol. 2011;104(2):535-542.
24. 6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut. 2010;59(11): 1516-1526.
25. Zou XP, Zhang B, Zhang XQ. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Human Pathology. 2009;40(11):1534-42.